Go­ing gang­busters: The top 20 biotech plat­form deals by up­front cash

For­tu­nate­ly, right at the time Re­gen­eron and Al­ny­lam were get­ting ready to break the news about their bil­lion-dol­lar part­ner­ship, Chris Doko­ma­ji­lar at Deal­For­ma was work­ing up a top-20 list of plat­form deals from the last decade.

With $800 mil­lion for the up­front and eq­ui­ty, the new deal lands right at the num­ber 2 spot for the in­dus­try, high­light­ing just how un­usu­al this pact is for such an ear­ly-stage al­liance. It’s al­so Re­gen­eron’s first big turn as the buy­er.

Drug de­vel­op­ers have been mov­ing up­stream more and more, and along wth a burst of M&A we’re al­so see­ing the ear­ly, ear­ly deals go­ing gang­busters, as Doko­ma­ji­lar notes in his as­sess­ment of the cur­rent trends:

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER